Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Revenue (2022 - 2025)

Historic Revenue for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $437602.0.

  • 60 Degrees Pharmaceuticals' Revenue rose 22344.76% to $437602.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $943721.0, marking a year-over-year increase of 9196.15%. This contributed to the annual value of $607574.0 for FY2024, which is 13960.52% up from last year.
  • 60 Degrees Pharmaceuticals' Revenue amounted to $437602.0 in Q3 2025, which was up 22344.76% from $100932.0 recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Revenue registered a high of $437602.0 during Q3 2025, and its lowest value of -$37174.0 during Q4 2022.
  • In the last 4 years, 60 Degrees Pharmaceuticals' Revenue had a median value of $115323.0 in 2024 and averaged $124244.1.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Revenue tumbled by 6956.45% in 2023 and then skyrocketed by 51538.55% in 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Revenue (Quarter) stood at -$37174.0 in 2022, then surged by 438.09% to $125681.0 in 2023, then soared by 92.26% to $241635.0 in 2024, then skyrocketed by 81.1% to $437602.0 in 2025.
  • Its Revenue was $437602.0 in Q3 2025, compared to $100932.0 in Q2 2025 and $163552.0 in Q1 2025.